Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Cougar Goes Public Through Reverse Merger, Raises $47M

April 10, 2006

By Jennifer Boggs

Aastrom Raising $25M For Adult Stem Cell Technology

April 7, 2006

By Jennifer Boggs

Aastrom Raising $25M For Adult Stem Cell Technology

April 7, 2006

By Jennifer Boggs

QLT, Retinagenix To Collaborate On Synthetic Retinoid Program

April 6, 2006

By Jennifer Boggs

QLT, Retinagenix To Collaborate On Synthetic Retinoid Program

April 6, 2006

By Jennifer Boggs

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

April 5, 2006

By Jennifer Boggs

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

April 5, 2006

By Jennifer Boggs

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

Merrimack's Series E: $65M For Autoimmune, Oncology

April 4, 2006

By Jennifer Boggs

Merrimack's Series E: $65M For Autoimmune, Oncology

April 4, 2006

By Jennifer Boggs

Medarex Begins Second Pivotal Study Of MDX-010 In Melanoma

April 3, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...